B. Klein, X. Zhang, and M. Jourdan, Paracrine rather than autocrine regulation of myeloma-cell growth and differentiation by interleukin-6, Blood, vol.73, pp.517-526, 1989.

M. Kawano, T. Hirano, and T. Matsuda, Autocrine generation and essential requirement of BSF-2/IL-6 for human multiple myeloma, pp.83-85, 1988.

Z. Gu, D. Vos, J. Rebouissou, and C. , Agonist anti-gp130 transducer monoclonal antibodies are human myeloma cell survival and growth factors, Leukemia, vol.14, issue.1
DOI : 10.1038/sj.leu.2401632

D. Vos, J. Couderc, G. Tarte, and K. , Identifying intercellular signaling genes expressed in malignant plasma cells by using complementary DNA arrays

Y. Wang, D. Vos, J. Jourdan, and M. , Cooperation between heparin-binding EGF-like growth factor and interleukin-6 in promoting the growth of human myeloma cells, Oncogene, vol.21, issue.16, pp.2584-2592, 2002.
DOI : 10.1038/sj.onc.1205355

D. Graus-porta, R. Beerli, J. Daly, and N. Hynes, ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling, The EMBO Journal, vol.16, issue.7
DOI : 10.1093/emboj/16.7.1647

R. Harris, E. Chung, and R. Coffey, EGF receptor ligands, Experimental Cell Research, vol.284, issue.1, pp.2-13, 2003.
DOI : 10.1016/S0014-4827(02)00105-2

D. Falls, Neuregulins: functions, forms, and signaling strategies, Experimental Cell Research, vol.284, issue.1, pp.14-30, 2003.
DOI : 10.1016/S0014-4827(02)00102-7

T. Yamauchi, K. Ueki, and K. Tobe, Tyrosine phosphorylation of the EGF receptor by the kinase Jak2 is induced by growth hormone EGFR and cancer prognosis ErbB-4: mechanism of action and biology, Nature. Eur J Cancer. Exp Cell Res, vol.39034284, issue.20, pp.91-96, 1997.

D. Slamon, W. Godolphin, and L. Jones, Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer, Science, vol.244, issue.4905, pp.707-712, 1989.
DOI : 10.1126/science.2470152

B. Bodey, B. Bodey, J. Groger, and A. , Clinical and prognostic significance of the expression of the c-erbB-2 and c-erbB-3 oncoproteins in primary and metastatic malignant melanomas and breast carcinomas, Anticancer Res, vol.17, pp.1319-1330, 1997.

D. Fry, Mechanism of action of erbB tyrosine kinase inhibitors, Experimental Cell Research, vol.284, issue.1, pp.131-139, 2003.
DOI : 10.1016/S0014-4827(02)00095-2

J. Mendelsohn and J. Baselga, The EGF receptor family as targets for cancer therapy, Oncogene, vol.19, issue.56, pp.6550-6565, 2000.
DOI : 10.1038/sj.onc.1204082

W. Slichenmyer, W. Elliott, and D. Fry, CI-1033, a pan-erbB tyrosine kinase inhibitor, Seminars in Oncology, vol.28, pp.80-85, 2001.
DOI : 10.1016/S0093-7754(01)90285-4

X. Zhang, J. Gaillard, and N. Robillard, Reproducible obtaining of human myeloma cell lines as a model for tumor stem cell study in human multiple myeloma, Blood, vol.83, pp.3654-3663, 1994.

M. Jourdan, D. Vos, J. Mechti, N. Klein, and B. , Regulation of Bcl-2-family proteins in myeloma cells by three myeloma survival factors: interleukin-6, interferon-alpha and insulin-like growth factor 1, Cell Death and Differentiation, vol.7, issue.12, pp.1244-1252, 2000.
DOI : 10.1038/sj.cdd.4400758

URL : https://hal.archives-ouvertes.fr/inserm-00130981

D. Vos, J. , J. M. Tarte, K. Jasmin, C. Klein et al., JAK2 tyrosine kinase inhibitor tyrphostin AG490 downregulates the mitogen-activated protein kinase (MAPK) and signal transducer and activator of transcription (STAT) pathways and induces apoptosis in myeloma cells, British Journal of Haematology, vol.83, issue.4, pp.823-828, 2000.
DOI : 10.1073/pnas.94.13.6764

R. Sun, Z. Lu, and J. Wijdenes, Large scale and clinical grade purification of syndecan-1+ malignant plasma cells, Journal of Immunological Methods, vol.205, issue.1, pp.73-79, 1997.
DOI : 10.1016/S0022-1759(97)00056-2

S. Stoll, S. Kansra, and S. Peshick, Differential Utilization and Localization of ErbB Receptor Tyrosine Kinases in Skin Compared to Normal and Malignant Keratinocytes, Neoplasia, vol.3, issue.4, pp.339-350, 2001.
DOI : 10.1038/sj.neo.7900170

M. Jourdan, X. Zhang, and M. Portier, IFN-alpha induces autocrine production of IL-6 in myeloma cell lines, pp.4402-4407, 1991.

Y. Shi, J. Hsu, L. Hu, J. Gera, and A. Lichtenstein, Signal Pathways Involved in Activation of p70S6K and Phosphorylation of 4E-BP1 following Exposure of Multiple Myeloma Tumor Cells to Interleukin-6, Journal of Biological Chemistry, vol.277, issue.18, pp.15712-15720, 2002.
DOI : 10.1074/jbc.M200043200

T. Hideshima, N. Nakamura, D. Chauhan, and K. Anderson, Biologic sequelae of interleukin-6 induced PI3-K/Akt signaling in multiple myeloma, Oncogene, vol.20, issue.42, pp.5991-6000, 2001.
DOI : 10.1038/sj.onc.1204833

R. Iwamoto, S. Yamazaki, and M. Asakura, Heparin-binding EGF-like growth factor and ErbB signaling is essential for heart function, Proceedings of the National Academy of Sciences, vol.98, issue.5
DOI : 10.1016/S0092-8674(00)80043-4

URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC152273